Help
Options
Didn't know it?
click below
click below
Knew it?
click below
click below
Don't Know
Remaining cards (0)
Know
retry
shuffle
restart
0:00
Embed Code - If you would like this activity on your web page, copy the script below and paste it into your web page.
Normal Size Small Size show me how
Normal Size Small Size show me how
Med II Midterm
Med Knowledge II Midterm
| Term | Definition |
|---|---|
| what is the brand name of apixaban | eliquis |
| what is the brand name of edoxaban | savaysa |
| what is the brand name of rivaroxaban | xarelto |
| what is the brand name of dabigatran | pradaxa |
| what is the brand name of enoxaparin | lovenox |
| what is the brand name of warfarin | coumadin/jantoven |
| what is the therapeutic class of apixaban | anticoagulant |
| what is the therapeutic class of edoxaban | anticoagulant |
| what is the therapeutic class of rivaroxaban | anticoagulant |
| what is the therapeutic class of dabigatran | anticoagulant |
| what is the therapeutic class of enoxaparin | anticoagulant |
| what is the therapeutic class of warfarin | anticoagulant |
| what is the therapeutic class of heparin | anticoagulant |
| what is the pharmacologic class of apixaban | factor Xa inhibitor |
| what is the pharmacologic class of edoxaban | factor Xa inhibitor |
| what is the pharmacologic class of rivaroxaban | factor Xa inhibitor |
| what is the pharmacologic class of dabigatran | direct thrombin inhibtor |
| what is the pharmacologic class of enoxaparin | low molecular weight heparin (LMWH) |
| what is the pharmacologic class of heparin | unfractionated heparin |
| what is the pharmacologic class of warfarin | vitamin k antagonist |
| what is the brand name of clopidogrel | plavix |
| what is the therapeutic class of clopidogrel | antiplatelet |
| what is the pharmacologic class of clopidogrel | P2Y12 inhibitor |
| what is the brand name of prasugrel | effient |
| what is the therapeutic class of prasugrel | antiplatelet |
| what is the pharmacologic class of prasugrel | P1Y12 inhibitor |
| what is the brand name of ticagrelor | brilinta |
| what is the therapeutic class of ticagrelor | antiplatelet |
| what is the pharmacologic class of ticagrelor | P2Y12 inhibitor |
| what is the brand name of dipyridamole+aspirin | aggrenox |
| what is the therapeutic class of dipyridamole+aspirin | antiplatelet |
| what is the pharmacologic class of dipyridamole+aspirin | salicylate+phosphodiesterase inhibitor |
| what is the MOA of apixaban | prevent the progression of Xa to activate thrombin |
| what is the MOA of edoxaban | prevent the progression of Xa to activate thrombin |
| what is the MOA of rivaroxaban | prevent the progression of Xa to activate thrombin |
| what is the MOA of dabigatran | inhibits factor II (thrombin) |
| what is the MOA of enoxaparin | inhibits mainly factor X with some II |
| what is the MOA of heparin | inhibits factors X and II |
| what is the MOA of warfarin | inhibits vitamin K dependent clotting factors (SNOT) |
| what is the MOA of clopidogrel | blocks P2Y12 receptor so platelet doesn't activate |
| what is the MOA of prasugrel | blocks P2Y12 receptor so platelet doesn't activate |
| what is the MOA of ticagrelor | blocks P2Y12 receptor so platelet doesn't activate |
| what is the MOA of dipyridamole+aspirin | blocks thromboxane A2 |
| what is the major characteristic of apixaban | bleeding risk |
| what is the major characteristic of edoxaban | bleeding risk |
| what is the major characteristic of rivaroxaban | bleeding risk |
| what is the major characteristic of dabigatran | bleeding risk |
| what is the major characteristic of enoxaparin | bleeding risk |
| what is the major characteristic of heparin | bleeding risk |
| what is the major characteristic of warfarin | Drug interactions |
| what is the major characteristic of clopidogrel | CYP activation |
| what is the major characteristic of prasugrel | CI in previous stroke |
| what is the major characteristic of ticagrelor | shortness of breath |
| what is the major characteristic of dipyridamole+aspirin | headache |
| what is the brand name of atorvastatin | lipitor |
| what is the therapeutic class of atorvastatin | antihyperlipidemic |
| what is the pharmacologic class of atorvastatin | HMG-CoA reductase inhibitor |
| what is the brand name of lovastatin | mevacor |
| what is the therapeutic class of lovastatin | antihyperlipidemic |
| what is the pharmacologic class of lovastatin | HMG-CoA reductase inhibitor |
| what is the brand name of pravastatin | pravachol |
| what is the therapeutic class of pravastatin | antihyperlipidemic |
| what is the pharmacologic class of pravastatin | HMG-CoA reductase inhibitor |
| what is the brand name of rosuvastatin | crestor |
| what is the therapeutic class of rosuvastatin | antihyperlipidemic |
| what is the pharmacologic class of rosuvastatin | HMG-CoA reductase inhibitor |
| what is the brand name of simvastatin | zocor |
| what is the therapeutic class of simvastatin | antihyperlipidemic |
| what is the pharmacologic class of simvastatin | HMG-CoA reductase inhibitor |
| what is the brand name of ezetimibe | zetia |
| what is the therapeutic class of ezetimibe | antihyperlipidemic |
| what is the pharmacologic class of ezetimibe | cholesterol absorption inhibitor |
| what is the brand name of fenofibrate | tricor |
| what is the therapeutic class of fenofibrate | antihyperlipidemic |
| what is the pharmacologic class of fenofibrate | fibric acid derivative |
| what is the brand name of gemfibrozil | lopid |
| what is the therapeutic class of gemfibrozil | antihyperlipidemic |
| what is the pharmacologic class gemfibrozil | fibric acid derivative |
| what is the brand name of niacin | niaspan |
| what is the therapeutic class of niacin | antihyperlipidemic |
| what is the pharmacologic class of niacin | nicotinic acid |
| what is the brand name of omega 3 acids | lovaza |
| what is the therapeutic class of omega 3 acids | antihyperlipidemic |
| what is the pharmacologic class of omega 3 acids | omega 3 fatty acid |
| what is the brand name of colsevelam | welchol |
| what is the therapeutic class of colesevelam | antihyperlipidemic |
| what is the pharmacologic class of colesevelam | bile acid sequestrant |
| what is the MOA of atorvastatin | inhibits cholesterol synthesis |
| what is the MOA of lovastatin | inhibits cholesterol synthesis |
| what is the MOA of pravastatin | inhibits cholesterol synthesis |
| what is the MOA of rosuvastatin | inhibits cholesterol synthesis |
| what is the MOA of simvastatin | inhibits cholesterol synthesis |
| what is the MOA of ezetimibe | inhibits absorption of cholesterol in the small intestines |
| what is the MOA of fenofibrate | increases breakdown of triglycerides in the blood |
| what is the MOA of gemfibrozil | increases breakdown of triglycerides in the blood |
| what is the MOA of niacin | decreases release of free fatty acids in the blood |
| what is the MOA of omega 3 acids | lower triglycerides and decrease inflammation |
| what is the MOA of colesevelam | prevents reabsorption of bile acids in the intestines |
| what is a major characteristic of atorvastatin | myopathy |
| what is a major characteristic of lovastatin | myopathy |
| what is a major characteristic of pravastatin | myopathy |
| what is a major characteristic of rosuvastatin | myopathy |
| what is a major characteristic of simvastatin | myopathy |
| what is a major characteristic of ezetimibe | liver dysfunction |
| what is a major characteristic of fenofibrate | liver dysfunction |
| what is a major characteristic of gemfibrozil | liver dysfunction |
| what is a major characteristic of niacin | flushing |
| what is a major characteristic of omega 3 acids | increased bleed risk |
| what is a major characteristic of colesevelam | constipation |
| what is the brand name of amiodarone | pacerone |
| what is the therapeutic class of amiodarone | antiarrythmic |
| what is the pharmacologic class of amiodarone | class III antiarrhythmic |
| what is the brand name of digoxin | lanoxin |
| what is the therapeutic class of digoxin | inotrope/antiarrhythmic |
| what is the pharmacologic class of digoxin | cardiac glycoside |
| what is the brand name of ranolazine | ranexa |
| what is the therapeutic class of ranolazine | antianginal |
| what is the pharmacologic class of ranolazine | cardiac sodium channel inhibitor |
| what is the MOA of amiodarone | blocks ion channels in the heart to help regulate rhythm and decrease heart rate |
| what is the MOA of digoxin | blocks Na/K pump to increase calcium inside cardiac muscles |
| what is the MOA of ranolazine | blocks cardiac sodium movement that is activated during ischemia |
| what is a major characteristic of amiodarone | has a large iodine moiety that leads to long term adverse effects |
| what is a major characteristic of digoxin | narrow therapeutic index, requires therapeutic drug monitoring |
| what is a major characteristic of ranolazine | CYP3A4 interactions/CI |
| what is the brand name of chlorthalidone | hygroton |
| what is the therapeutic class of chlorthalidone | antihypertensive |
| what is the pharmacologic class of chlorthalidone | thiazide like diuretic |
| what is the brand name of hydrochlorothiazide | microzide |
| what is the therapeutic class of hydrochlorothiazide | antihypertensive |
| what is the pharmacologic class of hydrochlorothiazide | thiazide diuretic |
| what is the brand name of triamterene/HCTZ | maxzide |
| what is the therapeutic class of triamterene/HCTZ | antihypertensive |
| what is the pharmacologic class of triamterene/HCTZ | potassium sparing/thiazide diuretic |
| what is the brand name of bumetanide | bumex |
| what is the therapeutic class of bumetanide | diuretic |
| what is the pharmacologic class of bumetanide | loop diuretic |
| what is the brand name of furosemide | lasix |
| what is the therapeutic class of furosemide | diuretic |
| what is the pharmacologic class of furosemide | loop diuretic |
| what is the brand name of torsemide | demadex |
| what is the therapeutic class of torsemide | diuretic |
| what is the pharmacologic class of torsemide | loop diuretic |
| what is the brand name of tolvaptan | samsca |
| what is the therapeutic class of tolvaptan | hyponatremia treatment |
| what is the pharmacologic class of tolvaptan | vasopressin antagonist |
| what is the MOA of chlorthalidone | increase electrolyte/water loss in the distal convoluted tubule |
| what is the MOA of hydrochlorothiazide | increase electrolyte/water loss in the distal convoluted tubule |
| what is the MOA of triamterene/HCTZ | blocks sodium channels in the late distal convoluted tubule |
| what is the MOA of bumetanide | increase electrolyte/water loss in the thick ascending loop of Henle |
| what is the MOA of furosemide | increase electrolyte/water loss in the thick ascending loop of Henle |
| what is the MOA of torsemide | increase electrolyte/water loss in the thick ascending loop of Henle |
| what is the MOA of tolvaptan | inhibits ADH mediated opening of water reabsorption channels in the collecting duct |
| what is a major characteristic of chlorthalidone | hyponatremia |
| what is a major characteristic of hydrochlorothiazide | hyponatremia |
| what is a major characteristic of triamterene/HCTZ | hyperkalemia |
| what is a major characteristic of bumetanide | hypokalemia |
| what is a major characteristic of furosemide | hypokalemia |
| what is a major characteristic of torsemide | hypokalemia |
| what is a major characteristic of tolvaptan | hypernatremia |
| what is the brand name of albuterol | proair/proventil/ventolin |
| what is the therapeutic class of albuterol | bronchodilator |
| what is the pharmacologic class of albuterol | SABA |
| what is the brand name of levalbuterol | xopenex |
| what is the therapeutic class of levalbuterol | bronchodilator |
| what is the pharmacologic class of levalbuterol | SABA |
| what is the brand name of ipratropium/albuterol | combivent |
| what is the therapeutic class of ipratropium/albuterol | dual bronchodilator |
| what is the pharmacologic class of ipratropium/albuterol | SABA/SAMA |
| what is the brand name of budesonide/formoterol | symbicort |
| what is the therapeutic class of budesonide/formoterol | anti-inflammatory/bronchodilator |
| what is the pharmacologic class of budesonide/formoterol | LABA/ICS |
| what is the brand name of fluticasone/salmeterol | advair diskus/wixela |
| what is the therapeutic class of fluticasone/salmeterol | anti-inflammatory/bronchodilator |
| what is the pharmacologic class of fluticasone/salmeterol | LABA/ICS |
| what is the brand name of fluticasone/vilanterol | breo ellipta |
| what is the therapeutic class of fluticasone/vilanterol | anti-inflammatory/bronchodilator |
| what is the pharmacologic class of fluticasone/vilanterol | LABA/ICS |
| what is the brand name of tiotropium | spiriva |
| what is the therapeutic class of tiotropium | bronchodilator |
| what is the pharmacologic class of tiotropium | LAMA |
| what is the brand name of fluticasone/umeclidinium/vilanterol | trelegy ellipta |
| what is the therapeutic class of fluticasone/umeclidinium/vilanterol | triple therapy |
| what is the pharmacologic class offluticasone/umeclidinium/vilanterol | LABA/LAMA/ICS |
| what is the brand name of budesonide/glycopyrrolate/formoterol | breztri aerosphere |
| what is the therapeutic class of budesonide/glycopyrrolate/formoterol | triple therapy |
| what is the pharmacologic class of budesonide/glycopyrrolate/formoterol | LABA/LAMA/ICS |
| what is the brand name of umeclidinium/vilanterol | anoro ellipta |
| what is the therapeutic class of umeclidinium/vilanterol | dual bronchodilator |
| what is the pharmacologic class of umeclidinium/vilanterol | LABA/LAMA |
| what is the MOA of albuterol | stimulate beta 2 receptors in the lungs to cause bronchodilation |
| what is the MOA of levalbuterol | stimulate beta 2 receptors in the lungs to cause bronchodilation |
| what is the MOA of ipratropium/albuterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/ block receptors where Ach binds preventing bronchoconstriction and promoting bronchodilation |
| what is the MOA of budesonide/formoterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/ inhibits transcription of inflammatory mediators in the lungs |
| what is the MOA of fluticasone/salmeterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/ inhibits transcription of inflammatory mediators in the lungs |
| what is the MOA of fluticasone/vilanterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/ inhibits transcription of inflammatory mediators in the lungs |
| what is the MOA of tiotropium | block receptors where Ach binds preventing bronchoconstriction and promoting bronchodilation |
| what is the MOA of fluticasone/umeclidinium/vilanterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/ inhibits transcription of inflammatory mediators in the lungs/block receptors where Ach binds preventing bronchoconstriction and promoting bronchodilation |
| what is the MOA of budesonide/glycopyrrolate/formoterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/ inhibits transcription of inflammatory mediators in the lungs/block receptors where Ach binds preventing bronchoconstriction and promoting bronchodilation |
| what is the MOA of umeclidinium/vilanterol | stimulate beta 2 receptors in the lungs to cause bronchodilation/block receptors where acetylcholine binds preventing bronchoconstriction and promoting bronchodilation |
| what is a major characteristic of albuterol | tachycardia |
| what is a major characteristic of levalbuterol | tachycardia |
| what is a major characteristic of ipratropium/albuterol | tachycardia/dry mouth |
| what is a major characteristic of budesonide/formoterol | tachycardia/oral thrush |
| what is a major characteristic of fluticasone/salmeterol | tachycardia/oral thrush |
| what is a major characteristic of fluticasone/vilanterol | tachycardia/oral thrush |
| what is a major characteristic of tiotropium | dry mouth |
| what is a major characteristic of fluticasone/umeclidinium/vilanterol | tachycardia/dry mouth/oral thrush |
| what is a major characteristic of budesonide/glycopyrrolate/formoterol | tachycardia/dry mouth/oral thrush |
| what is a major characteristic of umeclidinium/vilanterol | tachycardia/dry mouth |
| what is the brand name of metformin | glucophage |
| what is the brand name of glimepiride | amaryl |
| what is the brand name of glipizide | glucotrol |
| what is the brand name of pioglitazone | actos |
| what is the brand name of repaglinide | prandin |
| what is the brand name of canaglifozin | invokana |
| what is the brand name of dapaglifozin | farxiga |
| what is the brand name of empaglifozin | jardiance |
| what is the therapeutic class of metformin | antidiabetic |
| what is the therapeutic class of glimepiride | antidiabetic |
| what is the therapeutic class of glipizide | antidiabetic |
| what is the therapeutic class of pioglitazone | antidiabetic |
| what is the therapeutic class of repaglinide | antidiabetic |
| what is the therapeutic class of canaglifozin | antidiabetic |
| what is the therapeutic class of dapaglifozin | antidiabetic |
| what is the therapeutic class of empaglifozin | antidiabetic |
| what is the pharmacologic class of metformin | biguanide |
| what is the pharmacologic class of glimepiride | sulfonylurea |
| what is the pharmacologic class of glipizide | sulfonylurea |
| what is the pharmacologic class of pioglitazone | TZD |
| what is the pharmacologic class of repaglinide | meglitinide |
| what is the pharmacologic class of canaglifozin | SGLT-2 Inhibitor |
| what is the pharmacologic class of dapaglifozin | SGLT-2 Inhibitor |
| what is the pharmacologic class of empaglifozin | SGLT-2 inhibitor |
| what is the brand name of dulaglutide | trulicity |
| what is the brand name of exenatide | byetta/bydureon |
| what is the brand name of liraglutide | victoza |
| what is the brand name of semaglutide | ozempic |
| what is the brand name of tirzepatide | mounjaro |
| what is the brand name of saxagliptin | onglyza |
| what is the brand name of sitagliptin | januvia |
| what is the brand name of linagliptin | tradjenta |
| what is the brand name of semaglutide | wegovy |
| what is the brand name of tirzepatide | zepbound |
| what is the therapeutic class of dulaglutide | antidiabetic |
| what is the therapeutic class of exenatide | antidiabetic |
| what is the therapeutic class of liraglutide | antidiabetic |
| what is the therapeutic class of semaglutide | antidiabetic |
| what is the therapeutic class of tirzepatide | antidiabetic |
| what is the therapeutic class of saxagliptin | antidiabetic |
| what is the therapeutic class of sitagliptin | antidiabetic |
| what is the therapeutic class of linagliptin | antidiabetic |
| what is the therapeutic class of semaglutide | weight loss |
| what is the therapeutic class of tirzepatide | weight loss |
| what is the pharmacologic class of dulaglutide | GLP1 receptor agonist |
| what is the pharmacologic class of exenatide | GLP1 receptor agonist |
| what is the pharmacologic class of liraglutide | GLP1 receptor agonist |
| what is the pharmacologic class of semaglutide | GLP1 receptor agonist |
| what is the pharmacologic class of tirzepatide | GLP1-RA/GIP agonist |
| what is the pharmacologic class of saxagliptin | DPP4 inhibitor |
| what is the pharmacologic class of sitagliptin | DPP4 inhibitor |
| what is the pharmacologic class of linagliptin | DPP4 inhibitor |
| what is the pharmacologic class of semaglutide | GLP 1 agonist |
| what is the pharmacologic class of tirzepatide | GLP1 agonist |
| what is the MOA of metformin | decreased glucose production and improved glucose uptake into cells |
| what is the MOA of glimepiride | stimulate insulin release from pancreatic beta cells |
| what is the MOA of glipizide | stimulate insulin release from pancreatic beta cells |
| what is the MOA of pioglitazone | increases insulin sensitivity in muscle, fat, and liver cells |
| what is the MOA of repaglinide | work on pancreatic beta cells like sulfonylureas to stimulate insulin release |
| what is the MOA of canaglifozin | prevents glucose reabsorption in the kidneys to lower blood glucose levels |
| what is the MOA of dapaglifozin | prevents glucose reabsorption in the kidneys to lower blood glucose levels |
| what is the MOA of empaglifozin | prevents glucose reabsorption in the kidneys to lower blood glucose levels |
| what is the MOA of dulaglutide | exogenous GLP 1 hormone that stimulates insulin release |
| what is the MOA of exenatide | exogenous GLP 1 hormone that stimulates insulin release |
| what is the MOA of liraglutide | exogenous GLP 1 hormone that stimulates insulin release |
| what is the MOA of semaglutide | exogenous GLP 1 hormone that stimulates insulin release |
| what is the MOA of tirzepatide | exogenous GLP 1 hormone that stimulates insulin release |
| what is the MOA of saxagliptin | inhibits breakdown of glucagon like peptide 1 |
| what is the MOA of sitagliptin | inhibits breakdown of GLP 1 |
| what is the MOA of linagliptin | inhibits breakdown of GLP 1 |
| what is a major characteristic of metformin | diarrhea |
| what is a major characteristic of glimepiride | hypoglycemia risk |
| what is a major characteristic of glipizide | hypoglycemia risk |
| what is a major characteristic of pioglitazone | weight gain and edema |
| what is a major characteristic of repaglinide | hypoglycemia |
| what is a major characteristic of canaglifozin | increased risk of urogenital infections |
| what is a major characteristic of dapaglifozin | increased risk of urogenital infections |
| what is a major characteristic of empaglifozin | increased risk of urogenital infections |
| what is a major characteristic of dulaglutide | GI upset |
| what is a major characteristic of exenatide | GI upset |
| what is a major characteristic of liraglutide | GI upset |
| what is a major characteristic of semaglutide | GI upset |
| what is a major characteristic of tirzepatide | GI upset |
| what is a major characteristic of saxagliptin | cant use with GLP1 |
| what is a major characteristic of sitagliptin | cant use with GLP 1 |
| what is a major characteristic of linagliptin | cant use with GLP1 |
| what is the brand name of insulin glargine (U100) | lantus |
| what is the brand name of insulin glargine-yfgn U100 | semglee |
| what is the brand name of insulin glargine U300 | toujeo |
| what is the brand name of insulin degludec U100/U200 | tresiba |
| what is the brand name of NPH insulin U100 | humulin N/novolin N |
| what is the brand name of insulin lispro U100 | humalog |
| what is the brand name of insulin aspart U100 | novolog/fiasp |
| what is the brand name of insulin glulisine U100 | apidra |
| what is the brand name of regular U100 | humulin R/novolin R |
| what is the brand name of regular U500 | humulin R U500 |
| what is the therapeutic class of insulin glargine U100 | antidiabetic |
| what is the therapeutic class of insulin glargine-yfgn U100 | antidiabetic |
| what is the therapeutic class of insulin glargine U300 | antidiabetic |
| what is the therapeutic class of insulin degludec U100/U200 | antidiabetic |
| what is the therapeutic class of NPH insulin U100 | antidiabetic |
| what is the therapeutic class of insulin lispro U100 | antidiabetic |
| what is the therapeutic class of insulin aspart U100 | antidiabetic |
| what is the therapeutic class of insulin glulisine U100 | antidiabetic |
| what is the therapeutic class of regular U100 | antidiabetic |
| what is the therapeutic class of regular U500 | antidiabetic |
| what is the pharmacologic class of insulin glargine U100 | long acting insulin |
| what is the pharmacologic class of insulin glargine-yfgn U100 | long acting insulin |
| what is the pharmacologic class of insulin glargine U300 | long acting insulin |
| what is the pharmacologic class of insulin degludec U100/200 | long acting insulin |
| what is the pharmacologic class of NPH insulin U100 | intermediate acting insulin |
| what is the pharmacologic class of insulin lispro U100 | rapid acting insulin |
| what is the pharmacologic class of insulin aspart U100 | rapid acting insulin |
| what is the pharmacologic class of insulin glulisine U100 | rapid acting insulin |
| what is the pharmacologic class of regular U100 | short acting insulin |
| what is the pharmacologic class of regular U500 | short acting insulin |
| what is the MOA of insulin glargine U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of insulin glargine-yfgn U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of insulin glargine U300 | allows glucose to be taken up into cells for energy production |
| what is the MOA of insulin degludec U100/200 | allows glucose to be taken up into cells for energy production |
| what is the MOA of NPH insulin U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of insulin lispro U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of insulin aspart U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of insulin glulisine U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of regular U100 | allows glucose to be taken up into cells for energy production |
| what is the MOA of regular U500 | allows glucose to be taken up into cells for energy production |
| what is a major characteristic of insulin glargine U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of insulin glargine-yfgn U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of insulin glargine U300 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of insulin degludec U100/200 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of NPH insulin U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of insulin lispro U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of insulin aspart U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of insulin glulisine U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of regular U100 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is a major characteristic of regular U500 | hypoglycemia, weight gain, store in refrigerator, good for 28 days after taken out of refrigerator |
| what is the brand name of varenicline | chantix |
| what is the brand name of nicotine gum | nicorette gum |
| what is the brand name of nicotine lozenge | nicorette lozenge |
| what is the brand name of nicotine patch | nicoderm |
| what is the brand name of nicotine nasal spray | nicotrol |
| what is the brand name of bupropion SR | zyban |
| what is the therapeutic class of varenicline | smoking cessation |
| what is the therapeutic class of nicotine gum | smoking cessation |
| what is the therapeutic class of nicotine lozenge | smoking cessation |
| what is the therapeutic class of nicotine patch | smoking cessation |
| what is the therapeutic class of nicotine spray | smoking cessation |
| what is the therapeutic class of bupropion SR | smoking cessation |
| what is the pharmacologic class of varenicline | partial nicotine agonist |
| what is the pharmacologic class of nicotine gum | NRT |
| what is the pharmacologic class of nicotine lozenge | NRT |
| what is the pharmacologic class of nicotine patch | NRT |
| what is the pharmacologic class of nicotine spray | NRT |
| what is the pharmacologic class of bupropion SR | dopamine and norepi reuptake inhibitor |
| what is the MOA of varenicline | partially activates nicotine receptors to decrease cravings and withdrawal |
| what is the MOA of nicotine gum | replaces nicotine from cigarettes to stimulate nicotine receptor |
| what is the MOA of nicotine lozenge | replaces nicotine from cigarettes to stimulate nicotine receptor |
| what is the MOA of nicotine patch | replaces nicotine from cigarettes to stimulate nicotine receptor |
| what is the MOA of nicotine spray | replaces nicotine from cigarettes to stimulate nicotine receptor |
| what is the MOA of bupropion SR | increases dopamine in the neuronal synapse |
| what is a major characteristic of varenicline | vivid dreams/insomnia |
| what is a major characteristic of nicotine gum | n/v |
| what is a major characteristic of nicotine lozenge | mouth irritation |
| what is a major characteristic of nicotine patch | vivid dreams |
| what is a major characteristic of nicotine spray | nasal irritation |
| what is a major characteristic of bupropion SR | anorexia/weight loss |
| what is the brand name of codeine | n/a |
| what is the brand name of hydrocodone/APAP | norco |
| what is the brand name of oxycodone/APAP | percocet |
| what is the brand name of oxycodone | oxycontin |
| what is the brand name of morphine | MS contin |
| what is the brand name of tramadol | ultram |
| what is the brand name of buprenorphine/naloxone | suboxone |
| what is the brand name of naltrexone | vivitrol |
| what is the brand name of methylnaltrexone | relistor |
| what is the therapeutic class of codeine | analgesic |
| what is the therapeutic class of hydrocodone/APAP | analgesic |
| what is the therapeutic class of oxycodone/APAP | analgesic |
| what is the therapeutic class of oxycodone | analgesic |
| what is the therapeutic class of morphine | analgesic |
| what is the therapeutic class of tramadol | analgesic |
| what is the therapeutic class of buprenorphine/naloxone | opioid dependence |
| what is the therapeutic class of naltrexone | opioid/alcohol dependence |
| what is the therapeutic class of methylnaltrexone | constipation treatment |
| what is the pharmacologic class of codeine | opioid agonist |
| what is the pharmacologic class of hydrocodone/APAP | opioid agonist + APAP |
| what is the pharmacologic class of oxycodone/APAP | opioid agonist + APAP |
| what is the pharmacologic class of oxycodone | opioid agonist |
| what is the pharmacologic class of morphine | opioid agonist |
| what is the pharmacologic class of tramadol | opioid agonist + SNRI |
| what is the pharmacologic class of buprenorphine/naloxone | partial opioid agonist+opioid antagonist |
| what is the pharmacologic class of naltrexone | opioid antagonist |
| what is the pharmacologic class of methylnaltrexone | peripheral opioid antagonist |
| what is the MOA of codeine | stimulates opiate receptors to prevent signaling in pain pathways |
| what is the MOA of hydrocodone/APAP | stimulates opiate receptors to prevent signaling in pain pathways |
| what is the MOA of oxycodone/APAP | stimulates opiate receptors to prevent signaling in pain pathways |
| what is the MOA of oxycodone | stimulates opiate receptors to prevent signaling in pain pathways |
| what is the MOA of morphine | stimulates opiate receptors to prevent signaling in pain pathways |
| what is the MOA of tramadol | weak opiate with SNRI properties |
| what is the MOA of buprenorphine/naloxone | competes with and strongly binds to opiate receptor to stop opioid agonists from binding |
| what is the MOA of naltrexone | competes with and strongly binds to opiate receptor to stop opioid agonists from binding |
| what is the MOA of methylnaltrexone | competes with and strongly binds to opiate receptor to stop opioid agonists from binding |
| what is a major characteristic of codeine | respiratory depression and constipation |
| what is a major characteristic of hydrocodone/APAP | respiratory depression and constipation |
| what is a major characteristic of oxycodone/APAP | respiratory depression and constipation |
| what is a major characteristic of oxycodone | respiratory depression and constipation |
| what is a major characteristic of morphine | respiratory depression and constipation |
| what is a major characteristic of tramadol | respiratory depression and constipation |
| what is a major characteristic of buprenorphine/naloxone | withdrawal symptoms |
| what is a major characteristic of naltrexone | withdrawal symptoms |
| what is a major characteristic of methylnaltrexone | rapid bowel movement |
| what is the brand name of citalopram | celexa |
| what is the brand name of escitalopram | lexapro |
| what is the brand name of fluoxetine | prozac |
| what is the brand name of paroxetine | paxil |
| what is the brand name of sertraline | zoloft |
| what is the brand name of desvenlafaxine | pristiq |
| what is the brand name of venlafaxine | effexor |
| what is the brand name of duloxetine | cymbalta |
| what is the therapeutic class of citalopram | antidepressant |
| what is the therapeutic class of escitalopram | antidepressant |
| what is the therapeutic class of fluoxetine | antidepressant |
| what is the therapeutic class of sertraline | antidepressant |
| what is the therapeutic class of desvenlafaxine | antidepressant |
| what is the therapeutic class of venlafaxine | antidepressant |
| what is the therapeutic class of paroxetine | antidepressant |
| what is the therapeutic class of duloxetine | antidepressant |
| what is the pharmacologic class of citalopram | SSRI |
| what is the pharmacologic class of escitalopram | SSRI |
| what is the pharmacologic class of fluoxetine | SSRI |
| what is the pharmacologic class of paroxetine | SSRI |
| what is the pharmacologic class of sertraline | SSRI |
| what is the pharmacologic class of desvenlafaxine | SNRI |
| what is the pharmacologic class of venlafaxine | SNRI |
| what is the pharmacologic class of duloxetine | SNRI |
| what is a major characteristic of citalopram | withdrawal if stopped suddenly |
| what is a major characteristic of escitalopram | withdrawal if stopped suddenly |
| what is a major characteristic of fluoxetine | withdrawal if stopped suddenly |
| what is a major characteristic of paroxetine | withdrawal if stopped suddenly |
| what is a major characteristic of sertraline | withdrawal if stopped suddenly |
| what is a major characteristic of desvenlafaxine | withdrawal if stopped suddenly |
| what is a major characteristic of venlafaxine | withdrawal if stopped suddenly |
| what is a major characteristic of duloxetine | withdrawal if stopped suddenly |
| what is the MOA of citalopram | prevents serotonin from being reabsorbed by pre synaptic neurons so there is serotonin available to stimulate downstream neurons |
| what is the MOA of escitalopram | prevents serotonin from being reabsorbed by pre synaptic neurons so there is serotonin available to stimulate downstream neurons |
| what is the MOA of fluoxetine | prevents serotonin from being reabsorbed by pre synaptic neurons so there is serotonin available to stimulate downstream neurons |
| what is the MOA of paroxetine | prevents serotonin from being reabsorbed by pre synaptic neurons so there is serotonin available to stimulate downstream neurons |
| what is the MOA of sertraline | prevents serotonin from being reabsorbed by pre synaptic neurons so there is serotonin available to stimulate downstream neurons |
| what is the MOA of desvenlafaxine | prevents serotonin and norepinephrine from being reabsorbed by presynaptic neurons so there is extra to stimulate neurons downstream |
| what is the MOA of venlafaxine | prevents serotonin and norepinephrine from being reabsorbed by presynaptic neurons so there is extra to stimulate neurons downstream |
| what is the MOA of duloxetine | prevents serotonin and norepinephrine from being reabsorbed by presynaptic neurons so there is extra to stimulate neurons downstream |
| what is the brand name of amitriptyline | elavil |
| what is the brand name of nortriptyline | pamelor |
| what is the brand name of doxepin | silenor |
| what is the brand name of bupropion | wellbutrin |
| what is the brand name of mirtazapine | remeron |
| what is the brand name of trazodone | desyrel |
| what is the brand name of vilazodone | viibryd |
| what is the brand name of vortioxetine | trintellix |
| what is the therapeutic class of amitriptyline | antidepressant |
| what is the therapeutic class of nortriptyline | antidepressant |
| what is the therapeutic class of doxepin | antidepressant |
| what is the therapeutic class of bupropion | antidepressant |
| what is the therapeutic class of mirtazapine | antidepressant |
| what is the therapeutic class of trazodone | antidepressant |
| what is the therapeutic class of vilazodone | antidepressant |
| what is the therapeutic class of vortioxetine | antidepressant |
| what is the pharmacologic class of amitriptyline | TCA |
| what is the pharmacologic class of nortriptyline | TCA |
| what is the pharmacologic class of doxepin | TCA |
| what is the pharmacologic class of bupropion | NDRI |
| what is the pharmacologic class of mirtazapine | alpha-2 antagonist |
| what is the pharmacologic class of trazodone | SARI |
| what is the pharmacologic class of vilazodone | SSRI and 5-HT1A partial agonist |
| what is the pharmacologic class of vortioxetine | SMS |
| what is a major characteristic of amitriptyline | sedation and anticholinergic |
| what is a major characteristic of nortriptyline | sedation and anticholinergic |
| what is a major characteristic of doxepin | sedation and anticholinergic |
| what is a major characteristic of bupropion | vivid dreams and weight loss |
| what is a major characteristic of mirtazapine | weight gain and sedation |
| what is a major characteristic of trazodone | sedation |
| what is a major characteristic of vilazodone | must take with food |
| what is a major characteristic of vortioxetine | must be tapered |
| what is the MOA of amitriptyline | blocks reuptake of serotonin and norepinephrine by presynaptic neurons |
| what is the MOA of nortriptyline | blocks reuptake of serotonin and norepinephrine by presynaptic neurons |
| what is the MOA of doxepin | blocks reuptake of serotonin and norepinephrine by presynaptic neurons |
| what is the MOA of bupropion | blocks reuptake of norepinephrine and dopamine by presynaptic neurons |
| what is the MOA of mirtazapine | increases serotonin and norepinephrine release from presynaptic neurons |
| what is the MOA of trazodone | blocks reuptake of serotonin and histamine receptors |
| what is the MOA of vilazodone | blocks serotonin uptake and stimulates 5-HT1A receptor |
| what is the MOA of vortioxetine | blocks serotonin reuptake and modulates the postsynaptic activity of the serotonin receptors |
| what is the brand name of alprazolam | xanax |
| what is the brand name of clonazepam | klonopin |
| what is the brand name of clobazam | onfi |
| what is the brand name of diazepam | valium |
| what is the brand name of lorazepam | ativan |
| what is the brand name of temazepam | restoril |
| what is the brand name of triazolam | halcion |
| what is the brand name of buspirone | buspar |
| what is the brand name of gabapentin | neurontin |
| what is the brand name of pregabalin | lyrica |
| what is the therapeutic class of alprazolam | anxiolytic |
| what is the therapeutic class of clonazepam | anxiolytic |
| what is the therapeutic class of clobazam | anticonvulsant |
| what is the therapeutic class of diazepam | anxiolytic |
| what is the therapeutic class of lorazepam | anxiolytic |
| what is the therapeutic class of temazepam | sedative/hypnotic |
| what is the therapeutic class of triazolam | sedative/hypnotic |
| what is the therapeutic class of buspirone | anxiolytic |
| what is the therapeutic class of gabapentin | neuropathic pain |
| what is the therapeutic class of pregabalin | neuropathic pain |
| what is the pharmacologic class of alprazolam | benzodiazepine |
| what is the pharmacologic class of clonazepam | benzodiazepine |
| what is the pharmacologic class of clobazam | benzodiazepine |
| what is the pharmacologic class of diazepam | benzodiazepine |
| what is the pharmacologic class of lorazepam | benzodiazepine |
| what is the pharmacologic class of temazepam | benzodiazepine |
| what is the pharmacologic class of triazolam | benzodiazepine |
| what is the pharmacologic class of buspirone | serotonin 5-HT1A partial agonist |
| what is the pharmacologic class of gabapentin | GABA analog |
| what is the pharmacologic class of pregabalin | GABA analog |
| what is the MOA of alprazolam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of clonazepam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of clobazam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of diazepam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of lorazepam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of temazepam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of triazolam | bind to the gamma subunit of the GABA receptor to increase chloride influx into the neuron |
| what is the MOA of buspirone | partial agonist of the 5-HT1A receptor |
| what is the MOA of gabapentin | bind to calcium channels in the presynaptic neuron to reduce calcium influx |
| what is the MOA of pregabalin | bind to calcium channels in the presynaptic neuron to reduce calcium influx |
| what is a major characteristic of alprazolam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of clonazepam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of clobazam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of diazepam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of lorazepam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of temazepam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of triazolam | sudden withdrawal can cause seizures and death |
| what is a major characteristic of buspirone | needs to be tapered |
| what is a major characteristic of gabapentin | sedation |
| what is a major characteristic of pregabalin | sedation |
| what is the brand name of baclofen | lioresal |
| what is the brand name of carisoprodol | soma |
| what is the brand name of metaxalone | skelaxin |
| what is the brand name of methocarbamol | robaxin |
| what is the brand name of cyclobenzaprine | flexeril |
| what is the brand name of tizanidine | zanaflex |
| what is the therapeutic class of baclofen | muscle relaxant |
| what is the therapeutic class of carisoprodol | muscle relaxant |
| what is the therapeutic class of metaxalone | muscle relaxant |
| what is the therapeutic class of methocarbamol | muscle relaxant |
| what is the therapeutic class of cyclobenzaprine | muscle relaxant |
| what is the therapeutic class of tizanidine | muscle relaxant |
| what is the pharmacologic class of baclofen | GABA-B receptor agonist |
| what is the pharmacologic class of carisoprodol | centrally acting skeletal muscle relaxant |
| what is the pharmacologic class of metaxalone | centrally acting skeletal muscle relaxant |
| what is the pharmacologic class of methocarbamol | centrally acting skeletal muscle relaxant |
| what is the pharmacologic class of cyclobenzaprine | centrally acting skeletal muscle relaxant |
| what is the pharmacologic class of tizanidine | alpha-2 adrenergic agonist |
| what is a major characteristic of baclofen | requires tapering |
| what is a major characteristic of carisoprodol | dizziness/drowsiness |
| what is a major characteristic of metaxalone | dizziness/drowsiness |
| what is a major characteristic of methocarbamol | dizziness/drowsiness |
| what is a major characteristic of cyclobenzaprine | dizziness/drowsiness |
| what is a major characteristic of tizanidine | dizziness and low BP |
| what is the MOA of baclofen | binds to GABA-B receptors to increase inhibitory NT release |
| what is the MOA of carisoprodol | increases inhibitory NT and decreases excitatory NT in the CNS |
| what is the MOA of metaxalone | increases inhibitory NT and decreases excitatory NT in the CNS |
| what is the MOA of methocarbamol | increases inhibitory NT and decreases excitatory NT in the CNS |
| what is the MOA of cyclobenzaprine | increases inhibitory NT and decreases excitatory NT in the CNS |
| what is the MOA of tizanidine | increases inhibitory transmission in motor neurons to decrease muscle spasticity |
Created by:
lainey2790
Popular Pharmacology sets